Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal disease that causes scarring and thickening of the lung tissue leading to respiratory failure. Despite the approval of Pirfenidone and Nintedanib in multiple countries for the treatment of IPF, lung fibrosis remains a major unmet medical need. Bleomycin-induced pulmonary fibrosis has been a useful pre-clinical model in several species and is most prevalent in rodent models to evaluate potential prophylactic and therapeutic drugs for IPF. As a tissue injury and repair model of fibrosis, bleomycin (BLM) has contributed significantly to studies of the pathobiology of pulmonary fibrosis. The induction and progression of the disease in rodents is of a short duration, making it a practical model for evaluating test compounds in preclinical research. Major drawbacks for this model have been its high mortality rate and inconsistency in the induction of disease. At Aragen Bioscience, our extensive experience with this model has led to a proven track record of highly reproducible and successful preclinical studies. Aragen has run more than a hundred studies for our numerous clients which have resulted in pre-clinical data for multiple INDs.
Respiratory syncytial virus (RSV) infection is the major cause of severe respiratory illness in infants and young children, as well as immune compromised individuals and the elderly. It causes a range of illnesses varying from mild infection to life-threatening bronchiolitis and respiratory failure. Despite over 50 years of research, disease due to RSV infection remains an unmet medical need. Rodent models for testing efficacy and safety in preclinical studies provides a critical component to the development of anti-RSV antibodies, small molecules and vaccines. Aragen Bioscience offers both mouse and cotton rat RSV infection models as well as a wide range of functional readouts to assess the efficacy of anti-RSV biologics and small molecules. These models enable the development of customized study designs that are performed by trained personnel in dedicated work areas specifically designed for infectious disease models. We have now conducted more than 60 pre-clinical studies in rodent models of RSV infection (30-130 animals per study). While BALB/c mice (which are semi-permissive to RSV infection) provide quick information on preliminary proof of concept studies, the cotton rat (Sigmodon hispidus) model represents a clinically relevant model of RSV infection that can be used to develop next generation RSV therapeutics.
Allosteric inhibition of lysyl oxidase–like-2 impedes the development of a pathologic microenvironment. Nature Medicine 16, 1009–1017 (2010). The in-life portion of this study was performed at Aragen Bioscience.
Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients The Journal of Immunology, November 15, 2009 vol. 183 no. 10 6338-6345
An introduction to our services from concept to IND. 17 minutes
A case study highlighting the creation of a stable CHO cell line as well as the development of a scalable purification scheme suitable for cGMP production. The challenge of identifying and separating an inactive form of the protein of interest will be discussed. 15 minutes